Immunotherapy grants

Seed funding for early-stage, pre-development technology concepts in cancer immunotherapy; applicants must hold a tenure-track position at a not-for-profit research center or institution. Does not fund clinical trials or refinement of existing technologies.

Supports early-stage, pre-development concepts with potential to transform cancer immunotherapy. Targets bold, innovative technology ideas prior to formal development stage.

Supports team-based translational cancer immunology research bridging lab discovery and clinical application, focused on immune prevention/interception of primary cancer and recurrence. Candidates must hold tenure-track assistant professor or higher; not for-profit institutions excluded; clinical trials not funded.

Funds investigator-initiated phase I/II or II immunotherapy clinical trials emphasizing novel approaches, mechanistic investigation of clinical response, and predictive biomarker discovery/validation. PI must lead the study; research may be conducted at non-profit medical schools or research centers in the US or abroad (no support for for-profit institutions). Includes a co-funded chordoma-focused track with Chordoma Foundation.

Supports pioneering immunotherapy clinical trials designed and led by academic researchers. Requires a clinical trial focus; applicants must be academic investigators leading immunotherapy trials.

Supports innovative investigations at the intersection of laboratory discovery and clinical application in cancer immunology, accelerating translation of immunological discoveries into cancer therapies.

Supports the transition of distinguished postdoctoral researchers into independent tenure-track investigators in cancer immunotherapy. Targets early-career scientists at the postdoc-to-faculty transition stage.

Supports the transition of distinguished postdoctoral researchers into independent tenure-track investigators in cancer immunology.

For mid-career, tenure-track assistant or associate professors (M.D., Ph.D., or equivalent) with 3 years in that position, working on high-risk, high-reward cancer immunotherapy research; requires minimum 80% research time commitment; research must be conducted at non-profit medical schools or research centers, US or abroad (no for-profit institutions).

Supports mid-career scientists pursuing high-risk, high-reward research at the leading edge of cancer immunotherapy.

Postdoctoral fellowship in immunology/cancer immunology, must be conducted at a non-profit institution under a qualified faculty sponsor; open worldwide with no citizenship restrictions. Applicants must have <5 years mentored research experience post-PhD.

Supports postdoctoral scientists pursuing hypothesis-driven basic or translational cancer immunology combined with computational biology/data science training. Requires a formal sponsor (assistant professor or higher) and a co-sponsor at a non-profit host institution; no citizenship restrictions but applicants must have <5 years mentored research experience post-PhD.

Supports clinical research on lung, bowel, breast or prostate cancer conducted by comprehensive cancer infrastructures across EU Member States and Associated Countries. Covers innovative diagnostics, radiotherapy/surgery/chemotherapy, therapeutic cancer vaccines, and guideline implementation. Requires multi-stakeholder consortia, patient co-design, sex/gender-disaggregated data, and open science compliance via UNCAN.eu. Successful projects join the EU Cancer Mission 'Diagnosis and Treatment' cluster.